Navigation Links
CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
Date:1/21/2011

and metastasis," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals.  "CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumor cancers in that its unique mechanism of action disrupts the signaling of specific protein to protein binding between FAK and tumors."

CureFAKtor recently received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options.

About Focal Adhesion Kinase (FAK)Focal adhesion Kinase (FAK) is substantially over-expressed in many solid tumors. FAK operates by placing itself at the contact points between tumor cells and the extra cellular matrix that surrounds them. Studies by CureFAKtor and others found that in this role, FAK is an important facilitator for signals that cause tumor cells to survive, grow, and produce new blood vessels to sustain growth and travel to distant places within the body where they may establish new tumor sites. It also cocoons the tumor cells to protect them from the body's natural signaling mechanisms that would cause deviant tumor cells to be eliminated. In a similar fashion, FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies.  

About CureFAKtor PharmaceuticalsCureFAKtor Pharmaceuticals is a biopharmaceutical company focused on the research and development of Focal Adhesion Kinase therapies to prevent or treat cancer. CureFAKtor's investigational and combination therapy products target pancreatic, breast, colon, melanoma, lung and brain oncology disorders. CureFAKtor research is conducted at the Roswell Park Cancer Institute.  CureFAKtor is planning a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemothera
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. Amylin Pharmaceuticals to Webcast Year-End Financial Results
3. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
4. Federal Government Obtains Permanent Injunction Against Deltex Pharmaceuticals Inc.
5. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
6. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
7. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
8. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
9. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
10. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
11. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and ATLANTA , August 28, 2015 ... Food and Drug Administration (FDA) cleared the MagVita TMS Therapy ... patients who have failed to receive satisfactory improvement from prior ... technique for stimulating neural tissue in the part of the ... procedure has been proven safe and effective and MagVenture is ...
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... STEWARTVILLE, Minn., Sept. 12 Rochester,Medical Corporation ... publication of,results from a significant clinical study ... proprietary Infection Control Technology. The newly ... Internal Medicine",presents results of a randomized, double-blind, ...
... Include 1,000 mg Dose, PRINCETON, N.J., Sept. 12 ... discovery and development of novel,small molecule therapeutics, today announced ... multiple ascending dose (MAD) study of its lead,internal product ... with any of the doses under evaluation. As a ...
Cached Medicine Technology:Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial 2Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial 3Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 2Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 3Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 4
(Date:8/29/2015)... ... August 29, 2015 , ... People who have ... (including emphysema), or asthma, are at higher risk from wildfire smoke especially in ... failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of the stage ... short segment to the subject of diabetes. Diabetes is a debilitating health condition that ... recent advancements in medical science may prove to be a significant breakthrough that sufferers ...
(Date:8/28/2015)... ... , ... Rio Salado College joined nine educational institutions in Washington ... the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership ...
(Date:8/28/2015)... Las Vegas, Nevada (PRWEB) , ... August 28, 2015 , ... ... is announcing its decision to make the purchase of CPAP equipment more affordable by ... This offer includes all types of CPAP products and orders of any size. My ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment ... position they are applying for, they are unable to pass the initial drug test ... drug testing policies in order to be able to hire long-term, skilled talent. (1) ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... The percentage of physicians who provide free care to ... this is fast becoming huge problem for America’s quickly ... to a study conducted by the Center for Studying ... physicians provided charity care in the mid-1990s, compared with ...
... Institute of Technology has developed a new multi-functional sensing ... role in cystic fibrosis. // ,This ... tip of an atomic force microscope (AFM), creating a ... electrochemical activity at the cell surface. , ...
... Prolacta Bioscience, a for-profit company, started marketing a breast-milk concentrate ... their own milk on the Internet for $1 to $2.50 ... regulation and raise a lot of ethical and safety questions. ... at Presbyterian/St. Luke’s Medical Center said that this might affect ...
... well aware of Kawasaki as a motorcycle rather than a ... informed that his 9 year old daughter, Utkarsha was suffering ... as it is prevalent among Korean and Japanese children. 'I ... Kawasaki was a disease,' remarked Dinesh Ghai. ,Kawasaki ...
... found that babies born to women, who are hospitalized for ... APGAR scores and are more likely to be put under ... number of previous pregnancies, smoke more heavily and are less ... the April issue of Alcoholism: Clinical and Experimental Research. ...
... offer a pay of nearly $500,000 to the head of ... proposal, the Queensland Opposition has described it as being extravagant ... advertised for the post of a new director for the ... $500,000-plus. This is believed to pave way for enormous ...
Cached Medicine News:Health News:Fewer Doctors Treating For Free 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3Health News:Mama’s milk on sal 2Health News:Low Awareness Of Kawasaki Disease In Capital: Parents Form Support Group 2Health News:Use Of Alcohol During Pregnancy Affects Newborns 2
... laryngoscope handles can be used with Portex® ... sturdy chrome blades with long-lasting bronze fiber-optic ... for continuous routine use., ,The laryngoscope ... of sizes, from infant to large adult, ...
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
... Articulating Tip Laryngoscopes are the ... Industry. The articulating tip aids ... an improved view of epiglottis. ... Optic styles. We guarantee your ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: